Latest Aggregates News

Centuria Capital No. 2 Fund’s latest quarterly report confirms full compliance with note terms and stable financial arrangements, reassuring investors of its secure position.

Computershare Limited reported a 6.7% decline in revenue to $1.5 billion for the half-year ended December 2024, primarily due to the sale of its US Mortgage Services business. However, profit after tax from continuing operations surged 24.9% to $286.5 million, underpinning an interim dividend of AU 45 cents per share.

Alpha HPA has responded to ASX inquiries confirming the material market sensitivity of its signed Letter of Intent (LOI) and related surge in semiconductor sector sales, underscoring the strategic importance of its high purity materials.

KALINA Power has significantly expanded its land holdings in Alberta, boosting its potential Power-CCS capacity to 1.7 GW to meet surging demand for data centre power solutions with carbon capture.

Pinnacle Investment Management Group Limited has reported a remarkable 150.5% increase in net profit for the half year ended 31 December 2024, alongside a 16.7% rise in revenues and a healthy interim dividend announcement.

Alterity Therapeutics has raised over A$2 million through its U.S. ATM facility and expects nearly A$5.7 million in Australian tax rebates, fueling the advancement of its lead neurodegenerative drug candidate ATH434 following promising Phase 2 results.

Dateline Resources has released a promising scoping study for its Colosseum Gold Project in California, projecting robust gold production and revenue. The company is now progressing to a bankable feasibility study while exploring innovative uses for mining waste in the concrete industry.

X2M Connect reported a 51% revenue drop in Q2 FY25 as it shifts from hardware to SaaS, yet improved margins and EBITDA signal progress. Strategic partnerships in the Middle East and Taiwan offer promising growth avenues.

AustChina Holdings Limited reports steady progress in its Blackall Coal Project and copper investments, while exploring innovative coal processing technologies and assessing new mineral resource opportunities.

Pacific Current Group reports a 6.1% increase in total Funds Under Management to A$30 billion as of December 31, 2024, despite a decline in USD-denominated assets and exits from two boutique managers.

Alterity Therapeutics has reported positive Phase 2 results for ATH434, showing significant slowing of Multiple System Atrophy progression and a favorable safety profile. The trial demonstrated clinical benefits alongside reductions in brain iron accumulation, a key disease driver.

Argenica Therapeutics has dosed 80% of patients in its Phase 2 stroke trial and gained FDA orphan drug designations for its second candidate, ARG-006. The company reports a cash-positive quarter with $15 million in reserves.